IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SALVI, Annibale et

APPLICANT(S): al.

EXAMINER:

Unassigned

SERIAL NO.:

Unassigned

GROUP ART UNIT:

Unassigned

FILED:

November 3, 2003

Attorney Docket No.: P-6320-US

FOR.:

BASIC SALT OF THIOCTIC ACID WITH L-CARNITINE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes Form PTO-1449:

1.	listing documents including patents, publications, and other information for consideration
	by the Examiner, copies of which are included with this information disclosure statement;
2. 🗌	listing documents including patents, publications and other information that have been
	previously cited or submitted to the Patent Office in prior application U.S. Serial No.
	, filed which is properly identified and relied on for an earlier effective
	filing date under 35 U.S.C. 120 for consideration by the Examiner; however, in accordance
	with 37 C.F.R. 1.98(d), copies of such documents are not included in this information
	disclosure statement; and/or
3. 🔲	listing other information for the Examiner's consideration which was cited in a
	communication from a foreign patent office in a counterpart foreign application, a copy of
	which is included with this information disclosure statement.

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has APPLICANTS: SERIAL NO.: FILED:

I)

M

Page 2

SALVI, Annibale et al.

listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

subject Application into the national stage or before mailing of the first Office Action on
the merits of the subject Application or a request for continued examination thereof,
whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or
II) After the period specified in (I) but before the mailing date of either a final
Official Action under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311
whichever occurs first and;
1. the undersigned hereby states that each item of information listed on
the Form PTO-1449 was either (i) cited in a communication from a foreign patent
office in a counterpart foreign application not more than three (3) months prior to
the filing of this Information Disclosure Statement or (ii) not cited in a
communication from a foreign patent office in a counterpart foreign application,
and, to the knowledge of the undersigned after making reasonable inquiry, not
known to any individual designated in §1.56(c) more than three (3) months prior to
the filing of this information disclosure statement; or

Within three (3) months of filing the subject Application or entry of the

FILED: Page 3		
	2.	the undersigned hereby authorizes the Patent Office to charge the fee
	in the	amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.
III)		After the period in (I) and (II) but before the payment of the issue fee and,
	. 1.	The undersigned hereby states:
•		a)
		was cited in a communication from a foreign Patent Office in a counterpart
		foreign application not more than three (3) months prior to the filing of this
		Information Disclosure Statement; or
		b)
*		was cited in a communication from a foreign patent office in a counterpart
		foreign application, and to the knowledge of the undersigned after making
• .		reasonable inquiry, no item of information contained in this Information
		Disclosure Statement was known to any individual designated in 37 C.F.R. §
		1.56(c) more than three months prior to the filing of this Information
,		Disclosure Statement; and
	2.	The undersigned hereby authorizes the Patent Office to charge the

Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account

SALVI, Annibale et al.

APPLICANTS:

05-0649.

APPLICANTS:

SALVI, Annibale et al.

SERIAL NO.:

FILED: Page 4

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted,

Caleb Pollack

Attorney for Applicant(s) Registration No. 37,912

Dated: November 3, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP.

10 Rockefeller Plaza, Suite 1001 New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO			Compl te if Known			
			Application Number	Unassigned		
INFORMA	TION	DISCLOSURE	Filing Date			
STATEME	NT B	SY APPLICANT	First Named Inv ntor	SALVI, Annibal		
			Group Art Unit	, , , , ,		
(use as many sheets as n cessary)			Examiner Name			
Sheet	of		Attorney Docket Number	P-6320-US		

110 30 72 72 70 70 70 70 70 70 70 70 70 70 70 70 70						
U.S. PATENT DOCUMENTS						
Examiner Initials*	0.1-	U.S. Patent Document Number Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. 1					
	Α	5,916,912	·	AMES, Bruce N. et al.	June 29, 1999	
	ļ					· · · · · · · · · · · · · · · · · · ·
	ļ					
	<u> </u>				ļ <u>.</u>	
	ļ	, ,				
	<u> </u>					
·	ļ					
						
						· · · · · · · · · · · · · · · · · · ·
	ļ ·					
-						
	 	-		. ,		1
	ļ .					
	 					
·	-	<u> </u>				
	 	<u> </u>				
	<u> </u>					

·			FORE	IGN PATENT DOCUME	ENTS		
Examiner Initials*	Cite No. 1		gnPatent Document Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ'
	В	WIPO	WO 02/30919	LABORATORIO CHIMICO INTERNAZIONALE S.P.A.	April 18, 2002		
	С	WIPO	WO 02/30917	LABORATORIO CHIMICO INTERNAZIONALE S.P.A	April 18, 2002		
	D	WIPO	WO 02/30918	LABORATORIO CHIMICO INTERNAZIONALE S.P.A	April 18, 2002		É
	E	FR	4512	CENTRE D'ETUDE E DE REALISATIONS THERAPEUTIQUES (C.E.R.E.T.)	November 21, 1966		C
·							
<u>. </u>	<u> </u>						
	<u> </u>						
							70
	-						

	· · · · · · · · · · · · · · · · · · ·		
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not